Authorized purpose: Pre-procedural cardiovascular anatomy assessment, measurement, visualization, sizing, and planning support for transcatheter aortic valve replacement.
Clinical role
AI-assisted segmentation, reconstruction, landmark detection, multiplanar reformats, measurement, TAVR sizing, reporting, and C-arm planning support with user review and manual measurement available; not a stand-alone decision tool
Images and patients
CT/CTA · Heart and cardiovascular vessels, including the aortic valve/root, LVOT, annulus, aorta, ventricles, atria, myocardium, and pulmonary artery
Key limitation
Keep in mind: The indication is limited to patients with tricuspid aortic stenosis who are eligible for TAVR and have no prior aortic-valve implant. The software is not intended to be a decision-making tool by itself. Validation was technical measurement comparison and repeatability/usability testing, not a clinical-outcome study.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Pre-procedural cardiovascular anatomy assessment, measurement, visualization, sizing, and planning support for transcatheter aortic valve replacement.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and cardiovascular vessels, including the aortic valve/root, LVOT, annulus, aorta, ventricles, atria, myocardium, and pulmonary artery Input: Vendor-independent CT data in DICOM format for patients with tricuspid aortic stenosis who are eligible for TAVR and have no prior aortic-valve implant.
Who uses it?Intended users: Trained healthcare professionals including cardiologists, radiologists, and clinical specialists
What does the software produce?Output: Automatic full-heart and vessel segmentation; 2D/3D rendering; centerline and TAVR-plane detection; MPR; cardiac and aortic measurements; S-curve/C-arm angulation; downloadable 3D meshes; IFU-based TAVR sizing chart; and downloadable PDF or DICOM PDF reports.
What is its most important limitation?Key limitation: The indication is limited to patients with tricuspid aortic stenosis who are eligible for TAVR and have no prior aortic-valve implant. The software is not intended to be a decision-making tool by itself. Validation was technical measurement comparison and repeatability/usability testing, not a clinical-outcome study.
Clinical takeaway. Clinical role: Pre-procedural cardiovascular anatomy assessment, measurement, visualization, sizing, and planning support for transcatheter aortic valve replacement.
Evidence takeaway. Evidence from the reviewed source record: FDA packet: five technical validation studies covering 929 CT scans of TAVR-eligible patients without a prior aortic-position implant, including 289 U.S. and 640 European scans, compared automated measurements with expert ground truth. Annulus-parameter agreement exceeded 98% in U.S. studies and 97% in European studies; repeatability used 100 cases, and usability used 15 intended users across 105 scenarios.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Pre-procedural cardiovascular anatomy assessment, measurement, visualization, sizing, and planning support for transcatheter aortic valve replacement.
AI-assisted segmentation, reconstruction, landmark detection, multiplanar reformats, measurement, TAVR sizing, reporting, and C-arm planning support with user review and manual measurement available; not a stand-alone decision tool
Vendor-independent CT data in DICOM format for patients with tricuspid aortic stenosis who are eligible for TAVR and have no prior aortic-valve implant.
Automatic full-heart and vessel segmentation; 2D/3D rendering; centerline and TAVR-plane detection; MPR; cardiac and aortic measurements; S-curve/C-arm angulation; downloadable 3D meshes; IFU-based TAVR sizing chart; and downloadable PDF or DICOM PDF reports.
The indication is limited to patients with tricuspid aortic stenosis who are eligible for TAVR and have no prior aortic-valve implant. The software is not intended to be a decision-making tool by itself. Validation was technical measurement comparison and repeatability/usability testing, not a clinical-outcome study.
FDA packet: five technical validation studies covering 929 CT scans of TAVR-eligible patients without a prior aortic-position implant, including 289 U.S. and 640 European scans, compared automated measurements with expert ground truth. Annulus-parameter agreement exceeded 98% in U.S. studies and 97% in European studies; repeatability used 100 cases, and usability used 15 intended users across 105 scenarios.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA packet: five technical validation studies covering 929 CT scans of TAVR-eligible patients without a prior aortic-position implant, including 289 U.S. and 640 European scans, compared automated measurements with expert ground truth. Annulus-parameter agreement exceeded 98% in U.S. studies and 97% in European studies; repeatability used 100 cases, and usability used 15 intended users across 105 scenarios.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Hi-D Imaging 4TAVR regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K241984
Samplen=929
Sites5
IndependenceIndependence not established
K241984
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241984. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Vendor-independent CT data in DICOM format for patients with tricuspid aortic stenosis who are eligible for TAVR and have no prior aortic-valve implant.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Cloud-based SaMD in which users upload DICOM CT images and receive automated measurements, 2D/3D visualizations, and PDF/DICOM PDF reports; the FDA packet does not establish a specific local PACS, RIS, or EHR interface.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Hi-D Imaging 4TAVR as cloud-based software as a medical device that automatically processes DICOM images uploaded by the user and reports the results back to the user. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Hi-D Imaging 4TAVR (“the Device” or “4TAVR”) is a cloud-based software as a medical device (SaMD) intended for use by healthcare professionals" … "4TAVR automatically processes DICOM images uploaded by the user and reports the results back to the user.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automatic full-heart and vessel segmentation; 2D/3D rendering; centerline and TAVR-plane detection; MPR; cardiac and aortic measurements; S-curve/C-arm angulation; downloadable 3D meshes; IFU-based TAVR sizing chart; and downloadable PDF or DICOM PDF reports.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automatic full-heart and vessel segmentation; 2D/3D rendering; centerline and TAVR-plane detection; MPR; cardiac and aortic measurements; S-curve/C-arm angulation; downloadable 3D meshes; IFU-based TAVR sizing chart; and downloadable PDF or DICOM PDF reports.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Hi-D Imaging 4TAVR as cloud-based software as a medical device that automatically processes DICOM images uploaded by the user and reports the results back to the user. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Hi-D Imaging 4TAVR (“the Device” or “4TAVR”) is a cloud-based software as a medical device (SaMD) intended for use by healthcare professionals" … "4TAVR automatically processes DICOM images uploaded by the user and reports the results back to the user.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Cloud-based SaMD in which users upload DICOM CT images and receive automated measurements, 2D/3D visualizations, and PDF/DICOM PDF reports; the FDA packet does not establish a specific local PACS, RIS, or EHR interface.
ACR AI Central provides an exact-submission model card for Hi-D Imaging 4TAVR; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K241984 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: AI-CVD provides automated quantitative CT-derived anatomical and density measurements for clinician review, including calcium scores, cardiac and vascular measurements, lung and liver density, bone mineral density, and muscle/fat composition; it is opportunistic decision support, not diagnostic interpretation or risk prediction.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.